iPSCs: A Decade of Progress and Beyond
Organizer(s): Shinya Yamanaka, Haruhisa Inoue and Yanhong ShiDate: March 25 - 29, 2018
Location: Resort at Squaw Creek, Olympic Valley, CA, USA
The breakthrough discovery of iPSCs has transformed our prospects for regenerative medicine. The use of disease-specific iPSCs provides great hope for developing surrogate models of human diseases, platforms for drug discovery, and stem cell-based cell replacement therapies. Cutting-edge iPSC technologies, including small molecule-induced reprogramming, efficient lineage-specific differentiation, targeted gene editing, and comprehensive disease modeling will be highlighted in this symposium. The overall goals are to: 1) Promote a further understanding of the application of iPSC technology to model human diseases and develop new therapies; 2) Facilitate the integration of the iPSC technology with emerging technologies, such as CRISPR/Cas9 gene editing technology; 3) Stimulate the development of new technologies; and 4) Promote collaborations among the scientists attending. In a year when the Nobel prize-winning iPSC technology reaches its 10th anniversary, the prospect of using iPSC technology to observe the development of human diseases in a dish and to develop cell replacement therapies is truly tantalizing. However, the iPSC technology is still facing many challenges. This symposium will present the most recent advances in this rapidly evolving research area to address the needs of the field. Due to the enormous potential of the iPSC technology in disease modeling, drug discovery and therapeutic development, this symposium will appeal to a wide community of researchers and clinicians alike.
Scholarship Deadline: November 30 2017
Discounted Abstract Deadline: December 1 2017
Abstract Deadline: December 21 2017
Discounted Registration Deadline: January 18 2018
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Thermo Fisher Scientific Inc.